Subtopic Deep Dive

Foldamers
Research Guide

What is Foldamers?

Foldamers are abiotic oligomers engineered to adopt stable conformations mimicking protein secondary structures such as α-helices and β-sheets.

Foldamers include α/β-peptides, peptoids, and oligobenzamides designed for enhanced protease resistance and function. Key studies demonstrate their ability to inhibit protein-protein interactions (Azzarito et al., 2013; Horne et al., 2009). Over 20 papers from the provided list highlight synthesis methods like solid-phase peptoid assembly (Culf and Ouellette, 2010).

Curated Papers

Key Challenges

Why It Matters

Foldamers provide stable alternatives to natural peptides for disrupting protein-protein interactions, as shown in α-helix mimics inhibiting targets (Azzarito et al., 2013, 705 citations) and α/β-peptide foldamers blocking HIV gp41 binding (Horne et al., 2009, 270 citations). They enable protease-resistant antimicrobials and anticancer agents (Li et al., 2017; Chiangjong et al., 2020). Applications extend to therapeutics mimicking native surfaces without degradation issues.

Key Research Challenges

Achieving stable folding

Designing backbones with precise folding propensity remains difficult due to competing conformations. α/β-peptide foldamers require specific residue patterns for mimicry (Horne et al., 2009). Aromatic and hybrid systems face entropy barriers in aqueous environments (Azzarito et al., 2013).

Scalable synthesis methods

Solid-phase synthesis of peptoids and derivatives demands optimization for yield and purity (Culf and Ouellette, 2010). Ring-opening polymerization for polypeptides needs control over stereochemistry (Wu et al., 2018). Non-proteinogenic amino acid incorporation complicates large-scale production (Ding et al., 2020).

Biological activity optimization

Translating structural mimicry to in vivo efficacy requires tuning solubility and specificity. Oligobenzamides inhibit p53-hDM2 but face bioavailability hurdles (Plante et al., 2009). Antimicrobial foldamers need balanced membrane activity without toxicity (Li et al., 2017).

Essential Papers

Inhibition of α-helix-mediated protein–protein interactions using designed molecules

V. Azzarito, Kérya Long, Natasha S. Murphy et al. · 2013 · Nature Chemistry · 705 citations

Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design

Jianguo Li, Jun-Jie Koh, Shouping Liu et al. · 2017 · Frontiers in Neuroscience · 585 citations

Antimicrobial peptides (AMPs) are promising next generation antibiotics that hold great potential for combating bacterial resistance. AMPs can be both bacteriostatic and bactericidal, induce rapid ...

Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)

Wararat Chiangjong, Somchai Chutipongtanate, Suradej Hongeng · 2020 · International Journal of Oncology · 363 citations

Cancer is currently ineffectively treated using therapeutic drugs, and is also able to resist drug action, resulting in increased side effects following drug treatment. A novel therapeutic strategy...

Structural and biological mimicry of protein surface recognition by α/β-peptide foldamers

W. Seth Horne, Lisa M. Johnson, Thomas J. Ketas et al. · 2009 · Proceedings of the National Academy of Sciences · 270 citations

Unnatural oligomers that can mimic protein surfaces offer a potentially useful strategy for blocking biomedically important protein-protein interactions. Here we evaluate an approach based on combi...

New Advances in General Biomedical Applications of PAMAM Dendrimers

Renan Vinícius de Araújo, Soraya da Silva Santos, Elizabeth Igne Ferreira et al. · 2018 · Molecules · 252 citations

Dendrimers are nanoscopic compounds, which are monodispersed, and they are generally considered as homogeneous. PAMAM (polyamidoamine) was introduced in 1985, by Donald A. Tomalia, as a new class o...

The RaPID Platform for the Discovery of Pseudo-Natural Macrocyclic Peptides

Yuki Goto, Hiroaki Suga · 2021 · Accounts of Chemical Research · 222 citations

Although macrocyclic peptides bearing exotic building blocks have proven their utility as pharmaceuticals, the sources of macrocyclic peptide drugs have been largely limited to mimetics of native p...

Recent progress in stereoselective synthesis with aldolases

Pere Clapés, Wolf‐Dieter Fessner, Georg A. Sprenger et al. · 2010 · Current Opinion in Chemical Biology · 217 citations

Reading Guide

Foundational Papers

Start with Azzarito et al. (2013) for α-helix inhibition principles (705 citations), then Horne et al. (2009) for α/β-peptide mimicry evidence, followed by Culf and Ouellette (2010) on peptoid synthesis basics.

Recent Advances

Study Wu et al. (2018) for rapid polymerization advances and Ding et al. (2020) on non-proteinogenic amino acids in foldamer therapeutics.

Core Methods

Core techniques include solid-phase peptoid assembly (Culf and Ouellette, 2010), NCA ring-opening polymerization (Wu et al., 2018), and hybrid α/β-residue patterning for folding (Horne et al., 2009).

How PapersFlow Helps You Research Foldamers

Discover & Search

Research Agent uses searchPapers and citationGraph to map foldamer literature from Azzarito et al. (2013, 705 citations), revealing clusters around α-helix inhibitors. exaSearch uncovers niche synthesis papers like Culf and Ouellette (2010) on peptoids. findSimilarPapers expands from Horne et al. (2009) to related α/β-peptide mimics.

Analyze & Verify

Analysis Agent employs readPaperContent on Horne et al. (2009) to extract folding data, then verifyResponse with CoVe checks mimicry claims against structures. runPythonAnalysis processes citation networks or simulates helix propensity via NumPy. GRADE grading scores evidence strength for inhibition assays in Azzarito et al. (2013).

Synthesize & Write

Synthesis Agent detects gaps in peptoid applications beyond Culf and Ouellette (2010), flagging underexplored catalysis uses. Writing Agent applies latexEditText and latexSyncCitations to draft reviews citing 10+ foldamer papers, with latexCompile generating formatted manuscripts. exportMermaid visualizes folding pathways from oligobenzamide studies.

Use Cases

"Analyze folding stability data from α/β-peptide foldamers in Horne 2009"

Research Agent → searchPapers('Horne 2009 foldamers') → Analysis Agent → readPaperContent → runPythonAnalysis (NumPy plot of residue propensity vs. stability metrics) → researcher gets matplotlib graph of mimicry efficiency.

"Write LaTeX review on foldamer inhibitors of protein interactions"

Synthesis Agent → gap detection (Azzarito 2013 + Horne 2009) → Writing Agent → latexEditText('intro section') → latexSyncCitations → latexCompile → researcher gets compiled PDF with synced references and helix diagrams.

"Find GitHub repos with foldamer synthesis code"

Research Agent → searchPapers('peptoid synthesis code') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets repo links with solid-phase protocols from Culf 2010-inspired scripts.

Automated Workflows

Deep Research workflow scans 50+ foldamer papers via citationGraph from Azzarito et al. (2013), producing structured reports on helix mimicry trends. DeepScan applies 7-step analysis with CoVe checkpoints to verify peptoid synthesis claims (Culf and Ouellette, 2010). Theorizer generates hypotheses on hybrid foldamer catalysis from synthesis papers like Wu et al. (2018).

Try Doxa for Foldamers Research

Frequently Asked Questions

What defines foldamers?

Foldamers are abiotic oligomers designed to mimic protein secondary structures like α-helices with abiotic backbones such as α/β-peptides or peptoids for stability.

What are main synthesis methods?

Solid-phase synthesis produces N-substituted glycine oligomers (peptoids) (Culf and Ouellette, 2010). Ring-opening polymerization enables fast polypeptide assembly (Wu et al., 2018). Aldolases support stereoselective synthesis (Clapés et al., 2010).

What are key papers?

Azzarito et al. (2013, 705 citations) covers α-helix inhibitors. Horne et al. (2009, 270 citations) details α/β-peptide surface mimicry. Culf and Ouellette (2010, 178 citations) reviews peptoid synthesis.

What open problems exist?

Challenges include in vivo stability, scalable synthesis of complex backbones, and optimizing specificity for therapeutic targets beyond p53-hDM2 (Plante et al., 2009).